title: [Intraocular implantation of cyclosporine A drug delivery system in the treatment of experimental uveitis].
abstract: OBJECTIVE
  To investigate the effects and safety of cyclosporine A drug delivery system (CsA DDS) implanted into vitreous cavity on the treatment of experimental rabbit uveitis.
  
  
  METHODS
  A model of uveitis was established in 30 New Zealand white rabbits (30 eyes). The rabbits were randomized into control group (group A, 6 eyes), intravitreal non-medicated DDS group (group B, 6 eyes), oral CsA group (group C, 6 eyes) and intravitreal CsA DDS group (group D, 12 eyes). The inflammatory parameters such as floating cells, flaring and exudation in anterior chamber were graded. The cells infiltration and degree of opacity in vitreous were scored as well. The electroretinography and histopathological examination in eye, liver and kidney were recorded. In addition, CsA level in vitreous cavity was measured by HPLC in another 13 New Zealand white rabbits that received intravitreal implantation of CsA DDS.
  
  
  RESULTS
  Uveitis was successfully induced in the 30 eyes. The inflammation in groups A, B and C was more severe than group D. There was no significant difference between groups D and A or B (P < 0.05). The electroretinography showed more significant b-wave depression in groups A and B than group D (P < 0.05). A large amount of inflammatory cells infiltration and marked tissue disorganization were found at ciliary body and retina in groups A and B. The mean drug level in vitreous cavity ws (491.0 +/- 481.6) ng/ml at 4 weeks, (575.2 +/-0373.2) ng/ml at 8 weeks and (301.5 +/- 128.5) ng/ml at 12 weeks. No toxicity could be detected in histological examination by light microscopy.
  
  
  CONCLUSIONS
  Sustained therapeutic drug level could be achieved by implanting CsA DDS into vitreous cavity. It may effectively reduce the ocular inflammation in the rabbit model of uveitis.
authors.affiliation: Shandong Eye Institute, Qingdao 266071, China.
authors.forename: Xiao-guang
authors.initials: XG
authors.lastname: Dong
authors.forename: Yu-mei
authors.initials: YM
authors.lastname: Xu
authors.forename: Gong-qiang
authors.initials: GQ
authors.lastname: Yuan
authors.forename: Wei-yun
authors.initials: WY
authors.lastname: Shi
authors.forename: Li-xin
authors.initials: LX
authors.lastname: Xie
authors.forename: Shen-guo
authors.initials: SG
authors.lastname: Wang
mesh_terms: D000818:Animals; D016572:Cyclosporine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D004343:Drug Implants; D005260:Female; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D011817:Rabbits; D011897:Random Allocation; D014605:Uveitis / Q000188:drug therapy* / Q000473:pathology; D014822:Vitreous Body / Q000378:metabolism
chemical_list: D004343:Drug Implants; D007166:Immunosuppressive Agents; D016572:Cyclosporine